Company news

Oramed Pharmaceuticals Inc. news in 2021

Oramed Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.

View company

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

December 28, 2021

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

December 28, 2021

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

December 13, 2021

Oramed Pharmaceuticals Appoints Chief Legal Officer

December 7, 2021

Oramed to Join MSCI USA Small Cap Index

November 23, 2021

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

November 22, 2021

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

November 17, 2021

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

November 17, 2021

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

November 10, 2021

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

November 7, 2021

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

November 2, 2021

Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

October 28, 2021

Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

September 22, 2021

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

September 14, 2021

Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

August 23, 2021

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

August 9, 2021

Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference

August 8, 2021

Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021

August 4, 2021

Oramed Pharmaceuticals Appoints Chief Commercial Officer

July 28, 2021

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

July 20, 2021

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 21, 2021

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

June 7, 2021

Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine

May 24, 2021

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma

April 20, 2021

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

March 22, 2021

Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose

March 18, 2021

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

March 18, 2021

Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

March 15, 2021

Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021

March 3, 2021

Oramed Issues Letter to Shareholders

January 26, 2021

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

January 20, 2021

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

January 6, 2021

Decks in 2021